References
- Kapoor P, Greipp PT, Morice WG, et al. Anti-CD20 monoclonal antibody therapy in multiple myeloma. Br J Haematol. 2008;141:135–148.
- Huang B, Li J, Liu J, et al. CD20-positive multiple myeloma: can conventional chemotherapy still be used to achieve ideal outcome for these patients? Leuk Lymphoma. 2016;57:335–340.
- Wu L, Adams M, Carter T, et al. Lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells. Clin Cancer Res. 2008;14:4650–4657.
- Bairey OS, Matityahu S, Sandbank Y. Relapse of aggressive myeloma after complete remission in secondary acute leukemia: coincidence or consequence? Leuk Lymphoma. 1993;12:147–151.
- Sivakumaran M, Parker A, Murphy A, et al. Multilobulated, multinucleated multiple myeloma. Br J Haematol. 1992;81:622–624.
- Kaiser U, Parwaresch MR. Giant plasma cell myeloma-report of three unusual cases. Eur J Haematol. 1991;46:48–50.
- Beltran G, Stuckey WJ. Nuclear lobulation and cytoplasmic fibrils in leukemic plasma cells. Am J Clin Pathol. 1972;58:59–64.
- Kurabayashi H, Miyawaki S, Murakami H, et al. Ultrastructure of multinucleated giant myeloma cells: report of one case. Am J Hematol. 1989;31:284–285.
- Ghevaert C, Fournier M, Bernardi F, et al. Non-secretory muliple myeloma with multinucleated giant plasma cells. Leuk Lymphoma. 1997;27:185–189.
- Savage DG, Zipin D, Bhagat G, et al. Hemophagocytic, non-secretory multiple myeloma. Leuk Lymphoma. 2004;45:1061–1064.
- Matsuoka A, Tochigi A, Kishimoto M, et al. Lenalidomide induces cell death in an MDS-derived cell line with deletion of chromosome 5q by inhibition of cytokinesis. Leukemia. 2010;24:748–755.